IRD Straddle Strategy
IRD (Opus Genetics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
IRD (Opus Genetics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $359.2M, a beta of 0.63 versus the broader market, a 52-week range of 0.9-5.81, average daily share volume of 910K, a public-listing history dating back to 2015, approximately 18 full-time employees. These structural characteristics shape how IRD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.63 indicates IRD has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a straddle on IRD?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current IRD snapshot
As of May 15, 2026, spot at $4.79, ATM IV 154.30%, IV rank 32.19%, expected move 44.24%. The straddle on IRD below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on IRD specifically: IRD IV at 154.30% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 44.24% (roughly $2.12 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IRD expiries trade a higher absolute premium for lower per-day decay. Position sizing on IRD should anchor to the underlying notional of $4.79 per share and to the trader's directional view on IRD stock.
IRD straddle setup
The IRD straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IRD near $4.79, the first option leg uses a $4.79 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IRD chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IRD shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.79 | N/A |
| Buy 1 | Put | $4.79 | N/A |
IRD straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
IRD straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on IRD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on IRD
Straddles on IRD are pure-volatility plays that profit from large moves in either direction; traders typically buy IRD straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
IRD thesis for this straddle
The market-implied 1-standard-deviation range for IRD extends from approximately $2.67 on the downside to $6.91 on the upside. A IRD long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current IRD IV rank near 32.19% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on IRD should anchor more to the directional view and the expected-move geometry. As a Healthcare name, IRD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IRD-specific events.
IRD straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IRD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IRD alongside the broader basket even when IRD-specific fundamentals are unchanged. Always rebuild the position from current IRD chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on IRD?
- A straddle on IRD is the straddle strategy applied to IRD (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With IRD stock trading near $4.79, the strikes shown on this page are snapped to the nearest listed IRD chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are IRD straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the IRD straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 154.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IRD straddle?
- The breakeven for the IRD straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IRD market-implied 1-standard-deviation expected move is approximately 44.24%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on IRD?
- Straddles on IRD are pure-volatility plays that profit from large moves in either direction; traders typically buy IRD straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current IRD implied volatility affect this straddle?
- IRD ATM IV is at 154.30% with IV rank near 32.19%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.